518 results about "Hepatitis B virus" patented technology

Disclosed herein are chimeric antisense compounds and methods for reducing HBV mRNA, DNA, and protein expression. Such methods, compounds, and compositions are useful for treating, preventing, or ameliorating HBV-related diseases, disorders, or conditions.

The invention discloses an application of a POK erythroid myelogenic factor ZBTB7A in resisting hepatitis B virus. Experiments prove that the overexpression of the ZBTB7A can significantly reduce the level of secreted HBV-related virus protein and significantly inhibit HBV transcription and replication, and a new potential target is provided for treatment of hepatitis B. The research prompts that the ZBTB7A can be used as a novel HBV host limiting factor, lays a foundation for developing novel antiviral drugs, provides more effective treatment schemes for clinical treatment, and has wide application prospects and market potential.

The invention provides antisense oligonucleotide for inhibiting expression of hepatitis B virus, and also relates to a pharmaceutical composition of the antisense oligonucleotide. The antisense oligonucleotide or / and the pharmaceutical composition of the antisense oligonucleotide can be used for preparing drugs for treating and / or preventing hepatitis B.

The invention relates to the field of immunology, and particularly discloses a TCR combination and application thereof, the TCR combination is used for recognizing HBV antigen epitopes, the TCR combination comprises a plurality of separated TCRs, the plurality of separated TCRs form two TCR groups, and the two TCR groups comprise a first TCR group and a second TCR group; wherein the first TCR group specifically recognizes a first antigen epitope, and the amino acid sequence of the first antigen epitope is as shown in SEQ ID NO: 1; the first TCR group specifically recognizes a first antigen epitope, the second TCR group specifically recognizes a second antigen epitope, the amino acid sequence of the second antigen epitope is shown as SEQ ID NO: 2, the second antigen epitope respectively and correspondingly recognizes different antigen epitopes, the hepatitis B virus specific TCR and the epitope thereof are screened out, and an important means can be provided for treatment of TCR-T immune cells infected by hepatitis B virus.

The present invention relates to a viral gene therapy vector for removing hepatitis B viruses, a preparation method therefor, and the use thereof, aiming to solve the problem in which existing viral gene therapy vectors can only inhibit the replication of hepatitis B viruses, but cannot remove virus cccDNA. The vector comprises a promoter, an intron, an enhancer, a nuclear localization signal (NLS) functional domain encoding gene of PGLYRP2 protein, an HBV DNA binding domain encoding gene of the PGLYRP2 protein, a secretory signal peptide functional domain encoding gene of the PGLYRP2 protein, an HBV nucleocapsid-binding functional domain encoding gene of the PGLYRP2 protein, and an IRES fragment. The viral gene therapy vector can remarkably promote the removal of HBVs in the liver of mice and is used for treatment of hepatitis B virus infection.

Provided herein are non-naturally occurring variants of the hepatitis B virus (HBV) Core protein, the HBV polymerase N-terminal domain, and the HBV polymerase C-terminal domain, as well as immunogenic fragments thereof. Fusion proteins comprising the HBV variants fused to a herpes simplex virus (HSV) glycoprotein (gD) sequence, as well as methods of using the fusion proteins, are also provided.

Provided herein are epigenetic-modifying DNA-targeting systems, such as CRISPR-Cas / guide RNA (gRNA) systems, for the transcriptional repression of Hepatitis B viral (HBV) genes to promote a cellular phenotype that leads to the reduction of HBV infection. In some embodiments, the epigenetic-modifying DNA-targeting systems bind to or target a target site of at least one gene or regulatory element thereof in a Hepatitis B viral DNA sequence in cell. In some aspects, the provided systems relate to the transcriptional repression of one or more Hepatitis B viral gene and / or regulatory element thereof. In some aspects, also provided herein are methods and uses related to the provided compositions, for example in repressing Hepatitis B viral replication and expression in connection with Hepatitis B infections.

The invention relates to the field of immunology, and particularly discloses a hepatitis B virus specific TCR combination and application, the hepatitis B virus specific TCR combination is used for recognizing HBV antigen epitopes, the hepatitis B virus specific TCR combination comprises a plurality of separated TCRs, the plurality of separated TCRs form two TCR groups, and the two TCR groups comprise a first TCR group and a second TCR group; wherein the first TCR group specifically recognizes a first antigen epitope, and the amino acid sequence of the first antigen epitope is as shown in SEQ ID NO: 1; the first TCR group specifically recognizes a first antigen epitope, the second TCR group specifically recognizes a second antigen epitope, the amino acid sequence of the second antigen epitope is shown as SEQ ID NO: 2, the second antigen epitope respectively and correspondingly recognizes different antigen epitopes, the hepatitis B virus specific TCR and the epitope thereof are screened out, and an important means can be provided for treatment of TCR-T immune cells infected by hepatitis B virus.

The invention discloses an application of a combination of entecavir, an ASO drug, an mRNA therapeutic vaccine and / or interferon in preparation of drugs for treating chronic hepatitis B. Entecavir and interferon have an antiviral effect, the ASO drug reduces hepatitis B surface antigen titer, and the mRNA therapeutic vaccine is high in immunization speed, so that the entecavir, ASO drug, mRNA therapeutic vaccine and / or interferon combination can inhibit virus replication, and can be used for treating chronic hepatitis B. The composition strikes hepatitis B virus from multiple angles and multiple levels, achieves a good, lasting and non-rebound antiviral effect, and can cure hepatitis B to a certain extent.

Use of PGLYRP2 gene and a related drug thereof. The present invention relates to the field of biopharmaceuticals, and in particular, to use of the PGLYRP2 gene and the related drug thereof. The present invention aims to solve the problem that existing drugs can only inhibit the replication of hepatitis B virus and cannot eliminate viral cccDNA. The PGLYRP2 gene is used for preparing a drug for treating a hepatitis B virus infection. The PGLYRP2 gene is used for preparing a drug for eliminating hepatitis B virus cccDNA. Also provided is a gene therapy vector for eliminating hepatitis B virus. The gene therapy vector comprises a promoter, an intron, an enhancer, and a PGLYRP2 gene encoding region. The HBV virus inhibition function and the cccDNA-eliminating effect of the PGLYRP2 protein are defined, so that the elimination of HBV in liver cells and a mouse liver can be significantly promoted.

The invention discloses an amide pyrrole compound and application thereof in medicines, and particularly relates to a compound as shown in a formula (I) or a stereoisomer, a tautomer, a nitrogen oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug of the compound as shown in the formula (I), and application of the amide pyrrole compound as a medicine. Particularly, the compound can be used as a medicine for treating and / or preventing hepatitis B. The compound has relatively good inhibitory activity on HBV (Hepatitis B Virus) and has small toxicity on cells. # imgabs0 #

The invention discloses an endogenous reference gene, a primer probe and a kit for quantitatively detecting HBV (Hepatitis B Virus) nucleic acid. The nucleotide sequence of the endogenous reference gene is shown as SEQ ID NO: 1 or SEQ ID NO: 2. Two endogenous reference gene sequences capable of being used for quantitatively detecting HBV nucleic acid and several groups of primer probes for endogenous reference gene detection and HBV nucleic acid gene detection are obtained through screening, quantitative detection of HBV nucleic acid can be rapidly and accurately achieved through the primer probes, the primer probes can be used for detecting HBV genotype A-I, and the detection range is wider.

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof:which inhibit the cellular entry of hepatitis B virus (HBV) and / or hepatitis D virus (HDV) or interfere with the function of the life cycle of HBV and / or HDV and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV and / or HDV infection. The invention also relates to methods of treating an HBV and / or HDV infection in a subject by administering a therapeutically effective amount of a compound of the present invention.

The invention belongs to the technical field of immune effect drugs, and discloses a dendritic cell albumin suspension and a preparation method and application thereof.The preparation method of the dendritic cell albumin suspension includes the following steps that isolated mononuclear cells PBMC are collected, and matured DCs are cultured in a laminar flow purification laboratory; loading the multi-valence hepatitis B virus antigen epitope peptide on the DC; and the DC cell albumin suspension is prepared. The CTL immune effect excited by the DC can effectively remove HBV viruses in an integrated state in liver cells, so that the conditions of patients with hepatitis B and cirrhosis are reversed until HBV antigens are negative, and the conditions are relieved fundamentally; in the immune response excited by DC, the effector CTL cells immediately play a role in clearing HBV viruses, and the memory T lymphocytes play a role in clearing HBV viruses in vivo for a long time, so that the condition of hepatitis B is continuously reversed. Reagents used in the DC culture process are completely localized. The cost is greatly reduced and is obviously lower than that of foreign countries, and popularization is facilitated; china gets rid of the history of long-term dependence on imported anti-hepatitis B viruses.

The present disclosure provides methods for treating HBV infection using combination therapies, and related kits and compositions for use. The components of the combination therapies include an inhibitor of HBV gene expression or an agent that reduces HBV antigenic load, and an anti-HBV antibody.

The invention discloses an application of a G quadruplex ligand and entecavir combined drug in resisting HBV (hepatitis B virus) infection, and relates to the technical field of HBV treatment drugs. The invention determines that a G quadruplex sequence and a G quadruplex structure exist in an HBV genome, G quadruplex ligands TMPyP4 and BRACO19 can be combined with the HBV G quadruplex structure and inhibit transcription and translation of HBV, and TMPyP4 and existing clinical drug ETV combined medication have obvious synergistic effect, which indicates that the HBV G quadruplex can be used as a new drug target for resisting virus infection. The results of the invention can provide new tools and ideas for clinical prevention and treatment of hepatitis B, especially have broad prospects in the aspects of development, clinical application and the like of anti-hepatitis B drugs and vaccines, and can also be directly applied to the field of scientific research or guide the development of inhibitors for inhibiting HBV life cycle. The invention has important application value for obtaining new anti-HBV drug targets and screening new drugs.

The invention discloses thymus dependent lymphocyte antigen epitope peptide of hepatitis B virus antigen and application, and belongs to the field of medical immunology and infectious pathology. The thymus dependent lymphocyte antigen epitope peptide of the hepatitis B virus antigen is characterized in that the amino acid sequence of the epitope peptide comprises any one or more of the following: SPTVWLSVI; an LPLLPIFFCL (low-performance liquid chromatography- CPTVQASKL, and CPTVQASKL; an LPSDFFPSI (Liquefied Peptide The amino acid sequence is an amino acid sequence obtained by removing or replacing a single amino acid of the amino acid sequence. The epitope peptide disclosed by the invention can be specifically combined with cytotoxic thymus dependent lymphocytes to stimulate the cytotoxic thymus dependent lymphocytes to activate, proliferate and differentiate, so that the immune effect of resisting the hepatitis B virus is exerted; the antigen peptides can be used for preparing therapeutic and prophylactic vaccines for hepatitis B virus infection, can also be used for preparing detection reagents for detecting hepatitis B virus specific cytotoxic thymus dependent lymphocytes, and have potential application value in prevention, treatment and diagnosis of hepatitis B.

Provided is a chimeric antisense compound comprising a modified oligonucleotide comprising 5′ W1-G1-S1-G2-W2 3′, wherein: W1 is a 5′ wing segment, W2 is a 3′ wing segment, G1 is a first gap segment, S1 is a first separator segment, and G2 is a second gap segment. Also provided is a method for decreasing HBV mRNA, DNA and protein expression. Such compounds and methods are useful to treat, prevent, or ameliorate HBV-related diseases, disorders or conditions.

The invention discloses a detection system for simultaneously detecting HBV (Hepatitis B Virus) DNA (Deoxyribose Nucleic Acid) and HBV RNA (Ribonucleic Acid) based on CRISPR-cas12a / cas13a. According to the invention, a PCR primer is designed to amplify conserved intervals of different genotypes of HBV DNA, and a PCR primer with a T7 promoter is designed to amplify a conserved sequence of HBV RNA. In the same detection system, crRNA of cas12a / cas13a can specifically recognize amplification products of the crRNA respectively, HBV DNA and HBV RNA can be detected in a single tube at the same time, and finally visual detection is achieved through direct color development of dual fluorescence. According to the method, HBV DNA and HBV RNA can be efficiently, specifically and accurately detected, so that the clinical antiviral curative effect of the chronic hepatitis B patient is better monitored, medication is guided, and accurate treatment on the chronic hepatitis B patient is facilitated.

The present disclosure encompasses engineered nucleases which recognize and cleave a recognition sequence within a Hepatitis B virus (HBV) genome. The engineered meganucleases described herein can exhibit improved characteristics, such as enhanced specificity and / or efficiency of indel formation, when compared to previously described HBV meganucleases. Further, the disclosure encompasses pharmaceutical compositions comprising engineered meganuclease proteins, nucleic acids encoding engineered meganucleases, and the use of such compositions for treating HBV infections or diseases associated with HBV infections.

The invention discloses a method for constructing a cancer assessment model, a cancer assessment system, a medium and electronic equipment. According to the evaluation model developed by the invention, the diagnosis efficiency of the hepatitis B virus related liver cancer is remarkably improved, and the evaluation model particularly shows excellent prediction performance in early-stage liver cancer and serum marker negative patients. Compared with a single marker and an existing scoring model, the cancer evaluation model constructed by the method has huge advantages in comprehensive indexes such as AUC, sensitivity and specificity. Although the introduced GP73 is a negative coefficient in the model, the diagnosis performance is effectively improved through the synergistic effect of the GP73 and other markers. The evaluation model constructed by the invention provides a reliable tool for non-invasive prediction and early screening of liver cancer, and has important clinical application value.

The present application relates to the field of biomedicine, and provides an epigenetic editing tool for targeting a hepatitis B virus gene and a use thereof.

The invention relates to the technical field of biological medicines, and particularly discloses a composition containing clausenamide and application of the composition in preparation of a medicine with a liver injury treatment effect. The composition containing the clausenamide is prepared from the clausenamide and an active compound, the active compound is selected from ergolactone and / or isosaxifolin. Researches show that the composition has the effect of resisting alcoholic liver injury; in addition, the compound also has an anti-hepatitis B virus effect. Therefore, the composition has important application value when being used as an effective component for preparing the medicine with the effect of treating the liver injury and the medicine with the effect of resisting the hepatitis B virus.

This disclosure provides an adenoviral vector comprising at least one modified capsid protein comprising the insertion or fusion of a first peptide partner, wherein the first peptide partner is covalently bonded to a second peptide partner that is joined to a decorating antigen by insertion or fusion; and wherein the decorating antigen comprises hepatitis B virus PreS1 and / or hepatitis B virus PreS2, or an immunogenic fragment thereof. The disclosure also provides a method of producing the adenoviral vector, and uses of the adenoviral vector in vaccines and pharmaceutical compositions.

The present invention encompasses engineered meganucleases which recognize and cleave a recognition sequence within an open reading frame (ORF) of the genome of at least two genotypes of the Hepatitis B virus (HBV). The present invention also encompasses methods of using such engineered meganucleases in a pharmaceutical composition and in methods for treating or reducing the symptoms of a HBV infection, or treating hepatocellular carcinoma (HCC). Further, the invention encompasses pharmaceutical compositions comprising engineered meganuclease proteins, nucleic acids encoding engineered meganucleases, and the use of such compositions for treating HBV infections or HCC.

The utility model belongs to the technical field of virus detection reagent tube storage equipment, and provides a quantitative reagent kit for hepatitis B virus nucleic acid detection, including a storage box for centrally storing virus reagent tubes, a protection mechanism for improving the protection effect of the device and preventing the reagent tubes from shaking and causing breakage is arranged above the storage box, and a constant temperature mechanism for improving the preservation effect of the reagent tubes is arranged on the outside of the storage box; the utility model can greatly improve the protection safety provided by the virus reagent tubes when they are placed inside the storage box to a certain extent through the protection mechanism, the flip shaft and protection cover plate provided in the protection mechanism not only facilitate the staff to take and put the reagent tubes, but the compression and cooperation of the sliding screw, the clamping plate and the rotator provided in the screw tightening assembly can effectively improve the safety and stability of the reagent tubes placed in the storage box, prevent the reagent tubes from shaking and colliding and causing breakage, and the sponge plate can also prevent damage to the reagent tubes on the basis of improving the compression effect.

The present disclosure relates to methods for generating an immune response for treating or preventing hepatitis B virus infection. The present disclosure also relates to methods for generating MHC-E and / or MHC-II restricted CD8+ T cells for treating or preventing hepatitis B virus infection.

A drug conjugate includes a structure shown by the following formula: Z-(linker-[R]m)n. In the formula, Z is a drug compound, R is a sugar, and m and n are independently an integer from 1 to 6. The drug compound Z is a hepatitis virus targeting drug, a hepatitis B virus (HBV) drug, an inhibitor of apoptosis protein (IAP) antagonist, a multidrug resistance (MDR) inhibitor, or analogues, precursors, prodrugs, derivatives thereof.

The present invention relates generally to compositions, systems and methods for modulating hepatitis B virus (HBV) by targeting gene repression. In particular, the present invention provides an epigenetically modified DNA targeting system, such as a CRISPR-Cas / guide RNA (gRNA) system, for transcriptional repression of hepatitis B virus genes to promote cell phenotypes that lead to reduced HBV infection. In some embodiments, the epigenetically modified DNA targeting systems of the present invention bind to or target a target site of at least one gene in the hepatitis B virus DNA sequence or a regulatory element thereof in a cell. In some aspects, the systems provided herein relate to transcriptional repression of one or more hepatitis B virus genes and / or regulatory elements thereof. In some aspects, the invention also provides methods and uses associated with the provided compositions, such as in repression of hepatitis B virus replication and expression associated with hepatitis B infection.

The invention discloses a hepatitis B virus monoclonal neutralizing antibody SY-4 as well as preparation and application thereof. The hepatitis B virus monoclonal neutralizing antibody is SY-4 and consists of a heavy chain and a light chain paired with the heavy chain, the amino acid sequences of the CDR1, the CDR2 and the CDR3 of the heavy chain of the SY-4 are DFSFSSHA, ISSYDGGTT and AKEGNAFRYFGWLPDYQYFGMDV in sequence, and the amino acid sequences of the CDR1, the CDR2 and the CDR3 of the light chain of the SY-4 are QRINSRY, AAS and QQYGNSPLCS in sequence. The hepatitis B virus monoclonal neutralizing antibody SY-4 provided by the invention is an HBV neutralizing antibody, has ADCP activity, can crossly recognize various HBV genotypes HBsAg, has a good biological function, and provides a new candidate antibody for prevention and treatment of hepatitis B virus.